AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 171 min read$CMND

HRT FINANCIAL LP sold $11K of CMND

HRT FINANCIAL LP sold 3,183 shares of Clearmind Medicine Inc. (CMND) at $3.32 on 2026-06-15.

Original reporting
SEC EDGAR · HRT FINANCIAL LP
Published Jun 17, 2026, 8:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CMND
Bearish
medium confidence
Mentioned
$CMND
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CMNDBearishLow
01

Why it matters

The newest fact is the disclosed open-market sale of 3,183 shares by a 10% owner at $3.3200/share, totaling about $10.6k, with holdings after the trade of 103,492 shares.

02

Market read

Traders may monitor CMND for follow-on insider activity, but this specific disclosure is small and lacks fundamental catalysts.

03

What to watch

No 10b5-1 plan is cited, but the article also provides no context on total holdings, prior sales cadence, or whether the sale was tax-related—factors that can reduce interpretability.

Relevance 3/10Novelty 6/10Timing: Filed 2026-06-17; sale dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Clearmind Medicine Inc. (CMND).

Company-level read

Ticker impact

$CMNDBearishMedium confidence
Context

HRT Financial LP, a 10% owner, sold 3,183 shares of Clearmind Medicine (CMND) on 2026-06-15 at $3.3200/share via an open-market sale.

Expected impact

Near-term pressure is possible, but magnitude should be limited given the disclosure is a small Form 4 sale without new company fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction (open-market sale) with no 10b5-1 plan and no accompanying operational/regulatory catalyst; such sales often have limited predictive power for price direction.

Market effects

Sector

Minimal; this is company-specific insider activity with no sector-wide signal.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10% owner sale can be driven by diversification/liquidity needs rather than bearish fundamentals, especially without any accompanying negative news.

Key entities

  • issuer
    Clearmind Medicine Inc.

    Subject of the Form 4 insider sale disclosure (CMND).

  • insider
    HRT Financial LP

    10% owner who sold 3,183 shares in an open-market transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CMND insider trading history →

Related articles

SEP 11
$CMNDMedAI 8/10

Clearmind Medicine Inc.: Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial

Clearmind Medicine Inc. (Nasdaq: CMND) has enrolled the first patients with Alcohol Use Disorder (AUD) in its CMND-100 clinical trial. The trial, evaluating the safety and efficacy of CMND-100, is being conducted at Hadassah Medical Center in Jerusalem. The company aims to advance its psychedelic-based treatment for AUD, with plans to achieve key clinical milestones. Clearmind's shares are listed on Nasdaq under the symbol 'CMND'.

finanznachrichten.de2 min
SEP 8
$CMNDMed

Clearmind Medicine Receives Yale IRB Approval For CMND-100 Trial

Clearmind Medicine (CMND) received Yale IRB approval to expand its Phase I/II trial for CMND-100, a treatment for alcohol use disorder. The trial will now include Yale School of Medicine, adding to sites like Johns Hopkins. CMND-100 showed positive safety results in earlier trials. CMND stock closed at $1.16, down 31.76%, and is trading at $1.12 premarket.

rttnews.com2 min
SEP 4
$CMNDMed

Clearmind Tumbles on Buying into Charging Robotics

Clearmind Medicine (CMND) agreed to buy a 51% stake in Charging Robotics, a wireless EV charging solutions provider, for $2.5M. The company will also lend Charging Robotics $1.5M at 4% interest. Charging Robotics' tech offers up to 10 kW continuous charging for automated parking and autonomous vehicles.

baystreet.ca1 min
SEP 1
$CMNDMedAI 8/10

Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled

Clearmind Medicine (CMND) has started Phase IIa of its trial for CMND-100, a treatment for Alcohol Use Disorder, with six patients enrolled. The trial is evaluating safety, tolerability, and preliminary efficacy. The company reported positive data from earlier trial phases, supporting continued development. CMND-100 is Clearmind's lead investigational psychedelic-based therapeutic.

sina.com.hk2 min
AUG 13
$CMNDMed

Clearmind Medicine Inc.: Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint

Clearmind Medicine (Nasdaq: CMND) said its independent DSMB approved advancing its FDA-regulated Phase I/II trial of CMND-100 for alcohol use disorder from Part A to Parts B and C. Part A met the primary safety endpoint in healthy participants. Part B will test 80 mg and 160 mg in AUD patients; Part C will test 160 mg in healthy participants.

finanznachrichten.de4 min